Servier Phase III colorectal cancer trial fails to meet primary endpoint

Global independent pharmaceutical group, Servier, has announced that the primary objective (progression free survival) of the Phase III SOLSTICE trial has not been met.

SOLSTICE was designed to evaluate the efficacy of LONSURF® (trifluridine/tipiracil) + bevacizumab, against capecitabine and bevacizumab, in first line unresectable metastatic colorectal cancer (mCRC) patients non-eligible for intensive therapy.